Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro-Reference-Cited by-同舟云学术

Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro

Published:2006-01 Issue:1 Volume:30 Page:54-59
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Xiao Zhijian,Wang Yi,Lu Lin,Li Zongjin,Peng Zhi,Han Zhongchao,Hao Yushu

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference27 articles.

1. Meisoindigo for the freatment of chronic myelogenous leukaemia;Xiao;Br J Haematol,2000

2. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China;Xiao;Leuk Lymphoma,2002

3. The clinical effect and mechanism of meisoindigo in chronic granulocytic leukaemia;Liu;Chin J Prac Intern Med,2000

4. Cooperative Group of Phase III Clinical Trial on Meisoindigo. Phase III clinical trial on meisoindigo in the treatment of chronic myelogenous leukemia. Chin J Hematol 1997;18:69–72.

5. Clinical application of research on angiogenesis;Folkman;N Engl J Med,1995

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19;European Journal of Medicinal Chemistry;2024-07

2. Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors;Journal of Medicinal Chemistry;2024-04-18

3. DBU-Mediated Dimerization: Facile Access to 9,9′-Bifluorenylidenes and Isoindigos;Synlett;2023-08-22

4. lncRNA H22954 Inhibits Angiogenesis in Acute Myeloid Leukemia through a PDGFA-dependent Mechanism;Recent Patents on Anti-Cancer Drug Discovery;2022-11

5. Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma;eBioMedicine;2022-04